ME1

Melodiol Global Health Stock Price

Symbol: ASX:ME1Market Cap: AU$1.1mCategory: Pharmaceuticals & Biotech

ME1 Share Price Performance

AU$0.001
0.00 (0.00%)
AU$0.001
0.00 (0.00%)
Price AU$0.001

ME1 Community Narratives

There are no narratives available yet.

Recent ME1 News & Updates

No updates

Melodiol Global Health Limited Key Details

AU$18.9m

Revenue

AU$18.1m

Cost of Revenue

AU$817.0k

Gross Profit

AU$36.3m

Other Expenses

-AU$35.5m

Earnings

Last Reported Earnings
Dec 31, 2023
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.032
Gross Margin
4.32%
Net Profit Margin
-187.73%
Debt/Equity Ratio
-232.0%

Melodiol Global Health Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About ME1

Founded
2015
Employees
n/a
CEO
William Lay
WebsiteView website
melodiolglobalhealth.com

Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023. Melodiol Global Health Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

Australian Market Performance

  • 7 Days: 1.1%
  • 3 Months: 8.3%
  • 1 Year: 14.7%
  • Year to Date: 7.4%
The market is up 1.1% over the last week, with the Financials sector leading the way, up 1.1%. As for the past 12 months, the market is up 15%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading